BridgePoint Medical, out of Plymouth, MN, has developed innovative new catheters designed to cross chronic total coronary occlusions in native arteries, and reopen myocardial blood flow through vessels that everyone has given up on. Currently undergoing clinical trials, the CrossBoss™ CTO Catheter and the Stingray™ CTO Re-Entry System are yet to receive FDA approval.
More from BridgePoint about the devices:
The Stingray™ CTO Re-Entry System has two components: The Stingray™ CTO Orienting Balloon Catheter and The Stingray™ CTO Re-Entry Guidewire Familiar coronary balloon catheter and guidewire designs are enhanced with custom features for CTO crossing without changing routine practice Flat shape of the Stingray™ CTO Orienting Balloon Catheter is intended to orient one exit port automatically toward the vessel true lumen upon low pressure inflation (4atm) The Stingray™ CTO Re-Entry Guidewire’s distal probe is designed for exit port selection and re-entry into the vessel true lumen
CrossBoss™ CTO Catheter
Bi-directional rotation of the proximal torque device with the FAST SPIN Technique is designed to aid in advancement of the CrossBoss™ CTO Catheter A 3.0F atraumatic rounded tip is designed for passage through the CTO The device is intended to cross directly through the CTO or bypass the obstruction via a subintimal path
Device info page: Stingray™ CTO Re-Entry System
Video below the fold showing off the devices in greater detail:
(hat tip: Daily Breeze via AdvaMed)